provide all available expertise and information to date giving the company full access to existing data and data developed pursuant to the CRADA.

The successful company will provide the necessary scientific, financial and organizational support to characterize and test the animals.

Background information is available from the above-referenced address. Patent applications and pertinent information not yet publicly described can be obtained under a Confidential Disclosure Agreement.

The CRADA aims include the rapid publication of research results and the timely exploitation of commercial opportunities. The CRADA partner will enjoy rights of first negotiation for licensing Government rights to any inventions arising within the scope of the agreement. The license option and commercialization of inventions shall not conflict with NIH Guidelines for the availability of transgenic/knockout animals (http://www1.od.nih.gov/wals/transgen.html).

The expected duration of the CRADA will be 2 years.

The role of the Laboratory of Metabolism in this CRADA will be as follows:

1. Isolate and characterize genomic clones of human CYP2D6 and CYP3A4.
2. Generate mice by standard injections of oocyte pronuclei and screen founders.
3. Characterize tissue specificity of expression.
4. Jointly publish research results.

The role of the Collaborator will be:

1. Characterize in vitro metabolism using hepatic microsomal fractions.
2. Evaluate in vivo pharmacokinetics with probe substrates and proprietary compounds.
3. Analyze the role of CYP2D6 and CYP3A4 on bioavailability and efficacy of test compounds.
4. Jointly publish research results.

Selection criteria for choosing the CRADA partner will include but not be limited to:

1. Ability to collaborate with NCI on further research and development of this technology. Demonstration of experience and expertise in this or related areas of technology and the ability to provide intellectual contribution to the ongoing research and development. Ability to accomplish objectives according to an appropriate timetable to be outlined in the Collaborator's proposal.
2. Willingness to comply with NIH IRP Guidelines for the Availability of Transgenic/Knockout Animals (http://www1.od.nih.gov/wals/transgen.html). The proposal should specifically address the methods by which the animals will be made available.
3. Demonstration of the resources (facilities, personnel and expertise) necessary to perform research, development and commercialization of this technology.
4. Commitment of reasonable effort and resources on research, development and commercialization of this technology.
5. Expertise in the commercial development, production, marketing and sales of products related to this area of technology.
6. The level of financial support the Collaborator will supply for CRADA-related Government activities.
7. A willingness to cooperate with the National Cancer Institute in the publication of research results.
8. An agreement to be bound by the DHHS rules involving human subjects, patent rights and ethical treatment of animals.
9. A willingness to accept the legal provisions and language of the NIH model CRADA with modifications to address selection criteria #2 and other minor modifications.
10. Provisions for distribution of patent rights to any inventions. Generally, the rights of ownership are retained by the organization which is the employer of the inventor, with (1) an irrevocable, nonexclusive, royalty-free license to the Government (when a company employee is the sole inventor) or (2) an option to negotiate an exclusive or nonexclusive license to the company on terms that are appropriate (when the Government employee is the sole inventor).

Dated: November 21, 1997.

Kathleen Sybert,

Acting Director, Technology Development and Commercialization Branch, National Cancer Institute, NIH.

[FR Doc. 97–31638 Filed 12–2–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Cancer Institute Special Emphasis Panel (SEP) meeting:

Name of SEP: Cancer Genetics Network—Informatics and Information Technology Group.

Date: December 9–10, 1997.

Time: December 9–7:30 p.m. to Recess. December 10—8:00 a.m. to Adjournment.

Place: Ramada Inn—Rockville, 1775 Rockville Pike, Rockville, MD 20852.

Contact Person: Gerald Lovinger, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 630C, 6130 Executive Boulevard, MSC 7405, Bethesda, MD 20892–7405, Telephone: 301/496–7987.

Purpose/Agenda: To review, discuss and evaluate grant applications.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: November 25, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–31636 Filed 12–02–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting of the National Cancer Institute Special Emphasis Panel (SEP):

Name of SEP: Informatics Support for Breast and Colon Cancer Cooperative Family Registries.

Date: December 8, 1997.

Time: 9:00 a.m. to Adjournment.

Place: Executive Plaza North, Conference Room C, 6130 Executive Boulevard, Bethesda, MD 20892.

Contact Person: Courtney M. Kerwin, Ph.D., M.P.H., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 630I, 6130

Executive Boulevard, MSC 7405, Bethesda, MD 20892–7405, Telephone: 301/496–7421.

Purpose/Agenda: To review, discuss and evaluate grant applications.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396; Cancer Biology Research; 93.397, Cancer Centers Support; 93:398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: November 25, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–31637 Filed 12–2–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and Human Development; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Child Health and Human Development Special Emphasis Panel (SEP) meeting:

Name of SEP: Molecular Basis of Male Infertility.

Date: December 1–2, 1997.

Time: December 1—6:00 p.m.—9:00 p.m. December 2—8:00 a.m.—adjournment.

Place: Marriott Hotel at Medical Center, 6580 Fannin Street, Houston, TX.

Contact Person: Ms. Anne Krey, Scientific Review Administrator, DSR, 6100 Executive Boulevard, Room 5E01, Bethesda, Maryland 20892, Telephone: 301–496–1485.

Purpose/Agenda: To evaluate and review a grant application.

This meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. The discussion of this application could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the application, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Program Nos. [93.864, Population Research and No. 93.865, Research for Mothers and Children], National Institutes of Health, HHS)

Dated: November 25, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–31635 Filed 12–2–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration (SAMHSA)

Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given of the following meeting of the SAMHSA Special Emphasis Panel II in December 1997.

A summary of the meeting may be obtained from: Ms. Dee Herman, Committee Management Liaison, SAMHSA, Office of Policy and Program Coordination (OPPC), Division of Extramural Activities, Policy, and Review, 5600 Fishers Lane, Room 17–89, Rockville, Maryland 20857. *Telephone:* (301) 443–7390.

Substantive program information may be obtained from the individual named as Contact for the meeting listed below.

The meeting will include the review, discussion and evaluation of individual contract proposals. These discussions could reveal personal information concerning individuals associated with the proposals and confidential and financial information about an individual's proposal. The discussion may also reveal information about procurement activities exempt from disclosure by statute and trade secrets and commercial or financial information obtained from a person and privileged and confidential. Accordingly, the meeting is concerned with matters exempt from mandatory disclosure in Title 5 U.S.C. 552b(c)(3), (4), and (6) and 5 U.S.C. App. 2, § 10(d).

Committee name: SAMHSA Special Emphasis Panel II.

Meeting Date: December 15, 1997.

Place: Holiday Inn, Chase Room, 5520 Wisconsin Avenue, Bethesda, MD 20815–4495.

Closed: December 15, 1997 9:00 a.m.—Adjournment.

Contact: Michael Backenheimer, Ph.D., Room 17–89, Parklawn Building, Telephone: (301) 443–4783 and FAX: (301) 443–3437.

Dated: November 26, 1997.

Jeri Lipov,

Committee Management Officer, SAMHSA.

[FR Doc. 97–31673 Filed 12–2–97; 8:45 am]

BILLING CODE 4162–20–P

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Notice of Receipt of Applications for Permit

The following applicants have applied for a permit to conduct certain activities with endangered species. This notice is provided pursuant to Section 10(c) of the Endangered Species Act of 1973, *as amended* (16 U.S.C. 1531, *et seq.*):

PRT–836807.

Applicant: Denise Freitag, Potomac, MD

The applicant requests a permit to import the sport-hunted trophy of one male bontebok (*Damaliscus pygargus dorcas*) culled from a captive herd maintained under the management program of the Republic of South Africa, for the purpose of enhancement of the survival of the species.

PRT–836777

Applicant: Kentucky Department of Fish and Wildlife, Frankfort, KY

The applicant requests a permit to import American peregrine falcons (*Falco peregrinus anatum*) from Canada for release as part of the Kentucky's peregrine falcon restoration program for the purpose of enhancement of the survival of the species. This notice covers activities conducted by the applicant over a five year period.

Written data or comments should be submitted to the Director, U.S. Fish and Wildlife Service, Office of Management Authority, 4401 North Fairfax Drive, Room 700, Arlington, Virginia 22203 and must be received by the Director within 30 days of the date of this publication.

Documents and other information submitted with these applications are available for review, *subject to the requirements of the Privacy Act and Freedom of Information Act,* by any party who submits a written request for a copy of such documents to the following office within 30 days of the date of publication of this notice: U.S.